Compugen (NASDAQ:CGEN) Earns Buy Rating from HC Wainwright

Compugen (NASDAQ:CGEN)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $4.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 102.02% from the company’s current price.

Separately, Weiss Ratings upgraded Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $5.00.

Compugen Trading Down 4.3%

Compugen stock opened at $1.98 on Monday. The firm has a market capitalization of $187.21 million, a price-to-earnings ratio of 5.21 and a beta of 2.78. The firm’s fifty day moving average price is $2.43 and its two-hundred day moving average price is $2.43. Compugen has a 1-year low of $1.43 and a 1-year high of $3.23.

Compugen (NASDAQ:CGEN) last posted its earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Compugen had a net margin of 47.56% and a return on equity of 42.57%. The company had revenue of $2.60 million during the quarter, compared to the consensus estimate of $1.28 million. During the same period in the previous year, the firm posted ($0.08) earnings per share. On average, research analysts forecast that Compugen will post -0.28 EPS for the current year.

Institutional Investors Weigh In On Compugen

Several institutional investors have recently bought and sold shares of CGEN. Renaissance Technologies LLC boosted its holdings in Compugen by 12.1% during the 1st quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock worth $3,478,000 after acquiring an additional 176,088 shares during the last quarter. WINTON GROUP Ltd grew its stake in shares of Compugen by 26.0% in the 2nd quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company’s stock worth $422,000 after acquiring an additional 40,614 shares in the last quarter. Platform Technology Partners grew its stake in shares of Compugen by 10.0% in the 1st quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 5,000 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Compugen in the second quarter valued at about $110,000. Finally, Glenmede Trust Co. NA lifted its position in shares of Compugen by 187.5% during the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 22,500 shares in the last quarter. Institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biotechnology company focused on developing therapeutics for cancer and other diseases involving the immune system. The company uses computational biology and artificial intelligence-driven approaches to identify potential drug targets and develop antibody-based immunotherapies designed to restore or enhance the immune system’s ability to recognize and attack tumors.

Compugen’s pipeline has included investigational immune checkpoint and immuno-oncology programs, including COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT.